DealBio
All collections

Investor Intelligence

10 Precision Medicine Investors in Europe

European investors with demonstrated activity across precision medicine, molecular diagnostics, medical imaging and genomics-enabled care.

Published
  • Precision Medicine
  • Molecular Diagnostics
  • Medical Imaging
  • Genomics
  • Europe
  • Series A

Precision-medicine investing in Europe spans imaging biomarkers, , genomics and therapeutics built around patient-specific biology. The category attracts both specialist healthcare funds and broader technology investors where clinical data, AI and disease biology converge.

DealBio selected 10 investors with evidenced relevance to in Europe, using current investor research, financing precedents and public verification where needed.

Adara Ventures

European venture firm investing in applied AI, digital health, data infrastructure and other technology-led companies.

Stage
Series A
Sector / Focus
Precision medicine · Medical imaging
Investment markets
Spain · Europe
Investor type
VC

Relevant investment

Adara Ventures participated in Quibim’s $50 million Series A in January 2025. Quibim develops foundational AI models that extract imaging biomarkers from MRI, CT and PET scans for patient characterisation and outcome prediction, giving Adara a direct precision-medicine precedent.

ARVO Venture Capital

Spanish venture investor backing technology and healthcare companies from early stage onward.

Stage
Series A
Sector / Focus
Precision medicine · Medical imaging
Investment markets
Spain
Investor type
VC

Relevant investment

ARVO Venture Capital participated in Quibim’s $50 million Series A in January 2025. Quibim develops AI-powered imaging biomarkers from MRI, CT and PET scans to support patient characterisation, treatment selection and outcome prediction.

Buenavista Equity Partners

Independent Spanish asset manager investing through venture-capital and other private-market strategies.

Stage
Series A
Sector / Focus
Precision medicine · Medical imaging
Investment markets
Spain
Investor type
VC

Relevant investment

Buenavista Equity Partners co-led Quibim’s $50 million Series A in January 2025. Quibim uses AI-powered imaging biomarkers to support precision medicine across oncology, immunology, neurology and metabolic disease, giving Buenavista direct exposure to and imaging-led care.

Build Collective

Early-stage investor backing technology companies with data, software and applied-AI advantages.

Stage
Series A
Sector / Focus
Precision medicine · Medical imaging · Personalized health
Investment markets
Spain
Investor type
VC

Relevant investment

Build Collective participated in Quibim’s $50 million Series A in January 2025. Quibim develops foundational imaging-AI models that derive patient-specific biomarkers from MRI, CT and PET scans, providing a direct precision-medicine investment precedent.

K Fund

European venture firm investing from pre-seed through growth across software, deep tech and healthcare.

Stage
Seed · Series A
Sector / Focus
Precision medicine · Medical imaging
Investment markets
Spain · Germany · Europe
Investor type
VC

Relevant investment

K Fund’s Leadwind participated in Quibim’s $50 million Series A in January 2025. Quibim applies foundational AI to medical imaging to derive biomarkers and patient-specific insights, linking K Fund directly to imaging-led precision medicine.

Partech

Global technology investment firm backing companies from seed through growth across Europe and other markets.

Stage
Series A
Sector / Focus
Precision medicine · Molecular diagnostics · Oncology
Investment markets
Spain · Europe
Investor type
VC

Relevant investment

Partech participated in Quibim’s $50 million Series A in January 2025 as an existing investor. Quibim develops AI-powered imaging biomarkers for precision medicine, giving Partech direct exposure to patient stratification and disease-specific imaging models.

Adamed Pharma

European pharmaceutical group with strategic investment activity across healthcare innovation.

Stage
Seed · Series A
Sector / Focus
Precision medicine · BioAI · Personalized health
Investment markets
France · Europe
Investor type
Strategic investor

Relevant investment

Adamed Pharma backed One Biosciences, a French precision-medicine company using clinical-grade single-cell profiling and AI-supported analysis to stratify patients and guide therapy development. The investment gives Adamed direct exposure to molecular diagnostics and patient-specific biological profiling.

Amino Collective

Early-stage life-sciences investor backing biotechnology, diagnostics and computational health companies.

Stage
Pre-seed · Seed · Series A
Sector / Focus
Precision medicine · BioAI · Personalized health
Investment markets
Switzerland · United Kingdom
Investor type
VC

Relevant investment

Amino Collective backed Hedera Dx, a Swiss molecular-diagnostics company developing tumour profiling from tissue, circulating tumour DNA and RNA samples. Hedera’s reports identify actionable alterations to inform oncology treatment, giving Amino a direct precision-medicine precedent.

Creathor Ventures

European venture firm investing in technology and healthcare companies from early stage onward.

Stage
Series A · Series B
Sector / Focus
Precision medicine · Biotechnology
Investment markets
Europe
Investor type
VC

Relevant investment

Creathor Ventures led a financing round of up to €14 million for Blueprint Genetics. Blueprint provides clinical genetic testing and AI-enabled variant interpretation for inherited diseases, giving Creathor a direct molecular-diagnostics and precision-medicine precedent.

Forbion

European life-sciences VC investing across biotechnology from company formation through growth.

Stage
Series A · Growth
Sector / Focus
Precision medicine · Biotechnology
Investment markets
Europe
Investor type
VC

Relevant investment

Forbion led Kynexis’ €57 million Series A in 2023. Kynexis is developing a precision therapeutic for cognitive impairment associated with schizophrenia using a genetically linked disease mechanism and a patient-selection strategy, giving Forbion a direct precision-medicine precedent in therapeutics.

Methodology

DealBio builds investor lists using structured investor research, demonstrated investment activity and current public verification where needed. The methodology highlights investors with evidenced relevance to the article’s sector, stage and geography.

Get the DealBio Pulse

Weekly insights on health and longevity startups, standout founders, key markets, and notable exits.

You can unsubscribe at any time.